TRIUMPH-5: The Trial That Will Actually Compare Retatrutide and Tirzepatide Head-to-Head
If you’ve been trying to figure out how retatrutide actually compares with tirzepatide — not via cross-trial guesswork, but in a real head-to-head trial — there’s exactly one Phase 3 trial designed to answer that question. It’s called TRIUMPH-5, and despite what the trial-numbering might suggest, it is not the same trial as the knee osteoarthritis study (that one is TRIUMPH-4). Here’s what TRIUMPH-5 is, who’s in it, and what its readout will actually settle.
TRIUMPH-5 is a Phase 3, randomized, active-comparator trial that compares retatrutide directly against tirzepatide over 80 weeks of treatment in adults with obesity. It is registered on ClinicalTrials.gov as NCT06662383 and is the first Phase 3 trial designed to produce direct, head-to-head retatrutide-versus-tirzepatide efficacy and safety data.
Until TRIUMPH-5 reports, every comparison between retatrutide and tirzepatide is necessarily a cross-trial comparison — different populations, different durations, different dose-titration schedules. Cross-trial comparisons are useful as rough orientation but unreliable for clinical decision-making. TRIUMPH-5 is the trial that will replace those informal comparisons with a single dataset where everything except the drug is held constant.
What TRIUMPH-5 Is Designed to Measure
TRIUMPH-5 randomizes participants to either retatrutide or tirzepatide, both administered as weekly subcutaneous injections, for 80 weeks of treatment. The primary endpoint is change in body weight from baseline. Secondary endpoints typically include responder rates at specific weight-loss thresholds, changes in cardiometabolic markers, and safety and tolerability across the full treatment period.
The 80-week duration is meaningful. Most Phase 3 obesity trials run 68 to 72 weeks. The longer TRIUMPH-5 timeline gives Lilly more room to capture both the depth of weight loss in each arm and the durability of that loss as participants approach the plateau most incretin-based therapies eventually reach.
What TRIUMPH-5 will not test: it is not designed as a diabetes trial. Glycemic outcomes will be tracked but are not the primary focus. The dedicated active-comparator data in adults with type 2 diabetes is expected from a separate trial in the broader retatrutide program.
Why Active-Comparator Trials Matter
An active-comparator trial compares two drugs against each other. A placebo-controlled trial compares one drug against a matching placebo. Both are useful, but they answer different questions.
Placebo-controlled trials answer the question: does this drug work? That is what TRIUMPH-1, TRIUMPH-2, TRIUMPH-4, and TRANSCEND-T2D-1 are designed to answer.
Active-comparator trials answer the question: does this drug work better than the existing alternative? That is the question every clinician and every payer will eventually ask about retatrutide vs tirzepatide. TRIUMPH-5 is the trial designed to produce a direct answer.
For a deeper look at how the two drugs compare today on what is already publicly known, see our retatrutide vs tirzepatide overview.
The Cross-Trial Picture Going In
Until TRIUMPH-5 reports, the rough comparison between the two drugs looks like this — with the strong caveat that none of these comparisons are valid for clinical decision-making.
Tirzepatide, in SURMOUNT-1 (its pivotal Phase 3 obesity trial), produced a mean 22.5% body-weight reduction at the highest dose at 72 weeks in adults with obesity without type 2 diabetes.
Retatrutide, in its Phase 2 trial (published in *The New England Journal of Medicine* in 2023), produced a mean 24.2% body-weight reduction at the highest dose at 48 weeks in a similar population. In the Phase 3 TRIUMPH-4 trial in adults with obesity and knee osteoarthritis, the highest dose produced a mean 28.7% body-weight reduction at 68 weeks.
Those numbers suggest retatrutide may produce somewhat deeper weight loss than tirzepatide in head-to-head conditions. They do not prove it. The differences in trial populations, dose schedules, and durations all influence the result. TRIUMPH-5 is the trial that will replace the suggestion with evidence.
What ‘Winning’ TRIUMPH-5 Looks Like
TRIUMPH-5 is a superiority trial. The pre-specified statistical hypothesis is that retatrutide will produce greater weight loss than tirzepatide at the primary endpoint. The trial succeeds for retatrutide if it achieves a statistically significant superiority — meaning, in plain language, that the difference between the two arms is large enough to be unlikely to be due to chance.
It’s worth being clear about what ‘superiority’ versus ‘non-inferiority’ actually means in this context. A superiority trial is designed to show that one drug beats another by a meaningful margin. A non-inferiority trial is designed only to show that one drug is not meaningfully worse than another, within a pre-specified margin of equivalence. The two designs answer different commercial questions and are typically used in different competitive situations.
If retatrutide produces deeper weight loss than tirzepatide by a clinically meaningful margin — for example, 4 to 6 percentage points or more on placebo-adjusted body-weight reduction — and does so without a meaningfully worse safety profile, the result reframes obesity-medicine prescribing.
If retatrutide produces similar or only marginally better weight loss, the result is more nuanced. Tirzepatide is already approved, well-characterized, and broadly available. A retatrutide-vs-tirzepatide non-inferiority result, while still scientifically informative, would not by itself justify switching established patients. The clinical conversation in that scenario shifts toward differences in safety, dosing convenience, and individual treatment response rather than headline efficacy.
Safety and Tolerability — the Tiebreaker
In active-comparator trials between drugs in the same class, the safety and tolerability profile often becomes the clinical tiebreaker.
Both retatrutide and tirzepatide are incretin-based therapies, and both produce gastrointestinal adverse events — nausea, diarrhea, vomiting, constipation — that are concentrated during dose escalation. Earlier retatrutide trials have shown adverse-event rates broadly consistent with the class, though some signals (such as dysesthesia) have appeared at modest rates that warrant tracking across the full Phase 3 program.
TRIUMPH-5 will produce, for the first time, side-by-side adverse-event rates for the two drugs in the same population. Even with similar primary-endpoint efficacy, a meaningful difference in tolerability — discontinuation rates, severity of GI events, dose-escalation completion — would shape clinical preference.
For broader background on retatrutide tolerability, see our retatrutide side effects page and the safety and tolerability research summary.
What TRIUMPH-5 Won’t Settle
TRIUMPH-5 is a single trial in a single population over a single duration. It does not, on its own, answer every question.
It does not directly compare retatrutide against semaglutide. That comparison remains cross-trial.
It does not address the long-term cardiovascular outcomes question, which is the focus of dedicated cardiovascular outcomes trials in the program.
It does not address real-world adherence, insurance coverage, or commercial positioning — those questions become answerable only after approval and real-world prescribing.
And it will not, on its own, change a current tirzepatide prescription. Clinical-decision frameworks adapt slowly, and a single trial result almost never drives an immediate switch in a chronic medication.
How TRIUMPH-5 Fits Into the Broader Approval Path
TRIUMPH-5 is not part of the initial New Drug Application package. Eli Lilly’s planned 2026 NDA submission is anchored by TRIUMPH-1 and TRIUMPH-2, with TRIUMPH-4 providing supportive evidence. TRIUMPH-5 is a longer-running trial designed to support post-approval label expansion, comparative-effectiveness claims, and clinical-guideline positioning.
That timing matters. By the time TRIUMPH-5 reports, retatrutide will likely already be either approved or in active FDA review. The TRIUMPH-5 result will therefore mostly affect prescribing patterns, payer formulary decisions, and clinical guidelines rather than the approval decision itself.
Comparative-effectiveness data also shapes how clinical guidelines categorize new entrants. Bodies like the American Diabetes Association and the Obesity Medicine Association typically take 12 to 24 months after approval to incorporate a new drug into formal recommendations, and head-to-head trial data is one of the most influential inputs into that integration. A TRIUMPH-5 result that lands a year or two after approval would feed directly into those guideline updates rather than the initial label.
For the latest summary of where retatrutide stands in the FDA review process, see our overview of whether retatrutide is FDA-approved and the running retatrutide approval updates.
Stay Updated
Want a single, plain-English summary when TRIUMPH-5 reports? Join our retatrutide updates list and we’ll send a one-page interpretation of the headline numbers and what they mean for clinical positioning.
Disclaimer
Retatrutide is an investigational medication. It is not approved by the FDA for any indication and is not commercially available. This post is educational and should not be interpreted as medical advice or as a recommendation for any specific treatment. For information about how our content is sourced and reviewed, see our editorial policy and medical review policy.
FAQ SECTION
When will TRIUMPH-5 report results?
TRIUMPH-5 is an 80-week active-comparator trial. Eli Lilly has not publicly committed to a specific readout date. Active-comparator trials of this design typically read out 18 to 24 months after the final participant is enrolled, which means TRIUMPH-5 results are expected after the initial retatrutide approval decision rather than before it. The trial’s status is tracked on ClinicalTrials.gov under NCT06662383.
Is TRIUMPH-5 the same as TRIUMPH-4?
No. TRIUMPH-4 was the Phase 3 trial in adults with obesity and knee osteoarthritis, which reported successful results in December 2025. TRIUMPH-5 is a separate, later trial designed as the head-to-head active-comparator study against tirzepatide in adults with obesity. They are distinct trials with different designs, populations, and ClinicalTrials.gov registrations.
Will TRIUMPH-5 compare retatrutide against semaglutide?
No. TRIUMPH-5’s active comparator is tirzepatide, not semaglutide. There is no current Phase 3 trial designed to produce direct head-to-head retatrutide-vs-semaglutide data. The retatrutide-vs-semaglutide comparison remains a cross-trial comparison and should be interpreted cautiously.
How does TRIUMPH-5 differ from a placebo-controlled trial like TRIUMPH-1?
TRIUMPH-1 randomizes participants to retatrutide or matching placebo and answers the question: does retatrutide work? TRIUMPH-5 randomizes participants to retatrutide or tirzepatide and answers the question: does retatrutide work better than the existing alternative? Both designs are valid, but they answer different questions. Approval decisions are usually based on placebo-controlled data; clinical preference often turns on active-comparator data.
Could TRIUMPH-5 fail and still leave retatrutide approved?
Yes. Retatrutide’s regulatory approval will be based on the TRIUMPH-1 and TRIUMPH-2 placebo-controlled data, with supportive evidence from TRIUMPH-4. A non-superior result in TRIUMPH-5 — meaning retatrutide and tirzepatide produce similar weight loss — would not affect approval but would change the comparative-effectiveness conversation in clinical guidelines and payer formularies.
